Beauty-Device Regulations in Spain & Latin America (2025): What Changed
In 2025, beauty-device compliance in Spain and Latin America hinges on stricter risk classification and new local registration rules for cosmetic and medical devices.
Spain & the EU: The Final MDR Transition Hurdle
For Spain, 2025 marks a critical inflection point as the full application of the EU Medical Device Regulation (MDR 2017/745) becomes the default standard for many legacy devices. While the transition periods for older certificates have largely lapsed, the real change in 2025 is the aggressive scrutiny of beauty devices that sit on the borderline between cosmetics and medical devices. Devices that emit energy (laser, IPL, ultrasound) or use magnetic fields to alter the skin's structure are now strictly classified as active medical devices, regardless of whether they are sold to consumers or professionals. Spanish authorities, following the European Commission's updated guidance, are now requiring these products to have a dedicated EUDAMED registration, a full technical file, and a rigorous post-market surveillance plan. The practical change for global brands is that a simple CE mark under the old Medical Device Directive or a mere cosmetic notification is no longer sufficient. Instead, the entire supply chain—from importer to distributor—must be documented to Spanish authorities, with a focus on clinical evaluation data proving safety and performance for the specific aesthetic claim.
Brazil (ANVISA): Reclassification and the New "Beauty" Category
In Latin America, Brazil remains the regulatory heavyweight, and 2025 has brought a significant shift under ANVISA's updated Resolution RDC 830/2023, which has now been fully implemented. The most notable change is the formal reclassification of certain aesthetic equipment. Devices previously registered as "non-invasive" Class II are now being pushed into Class III due to their risk profiles (e.g., high-intensity focused ultrasound or cryolipolysis). ANVISA has also introduced a distinct, simplified pathway for "low-risk" cosmetic devices like microcurrent toning devices and LED masks, provided they do not claim physiological or therapeutic effects. However, the catch in 2025 is the requirement for a Local Technical Representative (LAR) to hold the registration and the mandatory adoption of the INMETRO certification for electrical safety. Brands that fail to update their technical dossiers to align with the new INMETRO standards by the end of the year risk having their registrations suspended.
Mexico (COFEPRIS): Stricter Import Controls and the "Novelty" Clause
Mexico's regulatory landscape has been volatile, but 2025 sees COFEPRIS taking a much harder line on the importation of beauty devices. The key change is the enforcement of the "novelty" clause, which requires any device that is not a direct equivalent to a previously registered product to undergo a full health registry evaluation—a process that can take 12 to 18 months. This directly impacts AI-powered skincare devices or those using novel energy sources. Additionally, COFEPRIS is now requiring proof of compliance with specific Mexican electrical standards (NOM-001-SEDE) at the customs level, not just at the point of registration. For global manufacturers, this means the days of shipping devices to Mexico for testing post-clearance are over; testing must be completed and documented before the first unit enters the country.
The Great Divide: "Wellness" vs. "Medical" Claims
The most consequential shift across the region in 2025 is the clear regulatory separation between wellness and medical claims. Previously, many beauty devices were marketed under a "general wellness" umbrella—think anti-aging or skin-tightening—to avoid medical scrutiny. Regulators in Spain, Brazil, and Mexico have now closed this loophole. If the device's mechanism of action is to alter the physiology of the skin (e.g., stimulating collagen through heat or inducing cell apoptosis), it is a medical device. If it merely cleanses, hydrates, or massages, it is a cosmetic. This distinction is now codified in how these countries classify devices, forcing brands to make a strategic choice. In 2025, a device that claims to "reduce the signs of cellulite" is treated as a medical device in Spain and Brazil, whereas a claim to